Nabriva Therapeutics

Nabriva Therapeutics

A biopharmaceutical company focused on the research and development of antibiotics to treat serious infections

Nabriva Therapeutics is a publicly owned clinical stage biopharmaceutical company based in Dublin, Ireland that was founded in 2006 by Rodger Novak. It also has facilities in the US (King of Prussia, PA & San Diego, CA) and Austria (Vienna). It was incorporated as a spin-off from Sandoz GmbH Antibiotics Research Institute (ABRI) in Vienna.The company is engaged in the research and development to treat serious infections, with a focus on the pleuromutilin class of antibiotics.

Nabriva's leading product in its pipeline is Contepo, an investigational epoxide antibiotic with a broad spectrum of bactericidal Gram-negative and Gram-positive activity, including against most contemporary MDR strains. The company gained Contepo through the acquisition of Zavante Therapeutics, its original developer. The FDA has granted Contepo Qualified Infectious Disease Product (QIDP) and Fast Track designations for:

  • Complicated urinary tract infections (cUTI)
  • Complicated intra-abdominal infections (cIAI)
  • Hospital-acquired bacterial pneumonia (HABP) & Ventilator-associated bacterial pneumonia (VABP)
  • Acute bacterial skin and skin structure infections (ABSSSI)

As of November 2018, Nabriva completed the Submission of New Drug Application to the FDA.

Another product in Nabriva's pipeline is Lefamulin, which is a semi-synthetic compound that inhibits the synthesis of bacterial protein. It has completed two Phase 3 trials to evaluate the safety and efficacy of Lefamulin (via IV and oral) in the treatment of adults with community-acquired bacterial pneumonia (CABP).

The company is also exploring formulations of Lefamulin for pediatric use and for the treatment of other illnesses such as acute bacterial skin and skin structure infection (ABSSSI), sexually transmitted infections (STIs), ventilator-associated bacterial pneumonia (VABP), osteomyelitis, and prosthetic joint infections.

Nabriva has also completed a Phase 1 clinical trial for BC-7013, a semi-synthetic compound derived from pleuromutilin, for its potential to be developed as a topical treatment for Gram-positive infections, including uncomplicated skin and skin structure infections (uSSIs).

Funding

Venture

On October 28, 2009 Nabriva Therapeutics completed a venture capital round with $22 million in funding from Nomura Phase 4 Ventures, HBM Partners, Wellcome Trust, GLS Ventures, and Novartis Venture Fund.

Series B

On April 7, 2015 Nabriva Therapeutics completed their series B funding round with $120 million in funding from Vivo Capital (lead investor), OrbiMed (lead investor), EcoR1 Capital, Boxer Capital of Tavistock Life Sciences, HBM Partners, Phase4 Partners, Wellcome Trust, GLSV, and Novartis Venture Fund.

Long term loan

On December 21, 2018 Nabriva Therapeutics came to a long term loan agreement for a loan of $75 million from Hercules Capital; and $25 million was funded at the closing of the long term loan deal.

Timeline

May 29, 2020

Nabriva Therapeutics receives positive EU CHMP Opinion for XENLETATM (lefamulin) for the Treatment of Community-Acquired Pneumonia (CAP).

May 29, 2020

Nabriva Therapeutics announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of XENLETA (lefamulin) for the treatment of community-acquired pneumonia (CAP) in adults.

December 21, 2018

Long term loan agreement with Hercules Capital

On December 21, 2018 Nabriva Therapeutics came to a long term loan agreement for a loan of $75 million from Hercules Capital; and $25 million was funded at the closing of the long term loan deal.

May 7, 2015

Series B funding round

On April 7, 2015 Nabriva Therapeutics completed their series B funding round with $120 million in funding from Vivo Capital (lead investor), OrbiMed (lead investor), EcoR1 Capital, Boxer Capital of Tavistock Life Sciences, HBM Partners, Phase4 Partners, Wellcome Trust, GLSV, and Novartis Venture Fund.

January 17, 2010

Nabriva Therapeutics raises a $22,000,000 series B round from Wellcome Trust, HBM BioVentures and Novartis Venture Fund.

October 28, 2009

Venture funding round

On October 28, 2009 Nabriva Therapeutics completed a venture capital round with $22 million in funding from Nomura Phase 4 Ventures, HBM Partners, Wellcome Trust, GLS Ventures, and Novartis Venture Fund.

2006

Nabriva Therapeutics was founded by Rodger Novak.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
1 Result
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Francesco Maria Lavino

Chief Commercial Officer

Gary Sender

CFO

Jennifer Schranz

Chief Medical Officer

Robert Crotty

General Counsel

Steve Gelone

President & COO

Ted Schroeder

CEO

Further reading

Title
Author
Link
Type
Date

Nabriva snaps up Zavante for its market-ready antibiotic

GlobalData Healthcare

https://www.pharmaceutical-technology.com/comment/nabriva-therapeutic-antibiotics/

Web

Nabriva Therapeutics Completes Submission of New Drug Application to U.S. Food and Drug Administration for Intravenous CONTEPO™ to Treat Complicated Urinary Tract Infections

Nabriva Therapeutics

https://globenewswire.com/news-release/2018/11/01/1640975/0/en/Nabriva-Therapeutics-Completes-Submission-of-New-Drug-Application-to-U-S-Food-and-Drug-Administration-for-Intravenous-CONTEPO-to-Treat-Complicated-Urinary-Tract-Infections.html

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
May 29, 2020
BioSpace
If approved, XENLETA has the potential to be a first-in-class pleuromutilin antibiotic for the intravenous (IV) and oral treatment of adult patients with CAP in Europe CHMP opinion supported by robust safety and efficacy data from two global pivotal Phase 3 trials of XENLETA European Commission decision anticipated in the second half of 2020 DUBLIN, Ireland, May 29, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV) announced today that the Committee for Medicinal

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.